Sign In
Buy BSEM
$4.14
-0.0290 (-0.696%)
At Close: Jun 03, 2026
Biostem Technologies, Inc. (BSEM) Q4 2023 Earnings Call Transcript
09:17pm, Monday, 01'st Apr 2024
Biostem Technologies, Inc. (BSEM) Q4 2023 Earnings Call Transcript
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase
04:07pm, Monday, 01'st Apr 2024
-Project Continued Growth from Sales of AmnioWrap2®– –Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Techn
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase
04:05pm, Monday, 01'st Apr 2024
-Project Continued Growth from Sales of AmnioWrap2 ® - -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) --
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
08:01am, Thursday, 21'st Mar 2024
Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, FLORIDA, March 21, 2024 – BioStem Technologies Inc.
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
08:00am, Thursday, 21'st Mar 2024
POMPANO BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market
10:39am, Monday, 26'th Feb 2024
New York, N.Y. February 26, 2024 – PRISM MarketView announces the release of an insightful interview with BioStem Technologies‘ (OTC: BSEM) CEO, Jason Matuszewski, discussing the company's strateg
Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies
04:06pm, Tuesday, 30'th Jan 2024
BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for
BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role
08:31am, Thursday, 11'th Jan 2024
Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine markets POMPANO BEACH, FLORIDA, January 11, 2024 – BioStem Technologies Inc.
BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call
07:30am, Tuesday, 15'th Nov 2022
POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization
BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference
07:30am, Monday, 10'th Oct 2022
POMPANO BEACH, FLORIDA., Oct. 10, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC PINK: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercializ
BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results (OTC: BSEM)
01:31pm, Tuesday, 23'rd Aug 2022 InvestorsHub
BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results
POMPANO BEACH, FL -- August 23, 2022 -- InvestorsHub NewsWire -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended June 30, 2022.
Jason Matuszewski, Chief Executive Officer...
BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd
07:30am, Tuesday, 16'th Aug 2022
POMPANO BEACH, FLORIDA., Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization
BioStem Technologies Reports Record Breaking Second Quarter Sales
11:15am, Wednesday, 25'th Aug 2021
Company on P ace to E xceed 2020 Revenues in 2021
BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
09:00am, Tuesday, 27'th Jul 2021
Pompano Beach, Fl., July 27, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing element
BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.
09:00am, Friday, 23'rd Jul 2021
Pompano Beach, Fl., July 23, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing element
